bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate - Profile

« Back to Dashboard

What are the generic sources for bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate and what is the scope of freedom to operate?

Bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Summary for bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate

International Patents:	304
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate

Constraining patent/regulatory exclusivity:

10,548,846

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BIKTARVY	Tablets	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	30 mg/120 mg/ 15 mg	210251	1	2023-09-28
BIKTARVY	Tablets	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	50 mg/200 mg/ 25 mg	210251	3	2022-02-07

US Patents and Regulatory Information for bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No	10,385,067
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No	12,594,244		Y
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No	9,216,996		Y	Y

Expired US Patents for bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021	7,803,788
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018	6,642,245
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018	7,803,788

International Patents for bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate

Country	Patent Number	Title	Estimated Expiration
Argentina	100903
Australia	2015276860
Australia	2018203175

Supplementary Protection Certificates for bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2822954	1890030-8	Sweden		PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/18/1289, 2018-06-25; RAETTAD SKYDDSTID FOER TILLAEGGSSKYDD'; PRV HAR I BESLUT DEN 8 JULI 2025 RAETTAT SKYDDSTIDEN I FOELJANDE TILLAEGGSSKYDD I ENLIGHET MED PMD:S BESLUT PMAE 7804/24: 2290016-1, 2090020-5, 2090055-1, 1590060-8, 1890030-8, 1990012-5, 2190017-0, 1690040-9, 1790035-8, 2390005-3, 1990013-3, 2090009-8
2822954	C20180024 00269	Estonia		PRODUCT NAME: BIKTEGRAVIIR;REG NO/DATE: EU/1/18/1289 25.06.2018
2822954	CR 2018 00029	Denmark		PRODUCT NAME: BICTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BICTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/18/1289 20180625

Investment Analysis of Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide Fumarate Combination

Last updated: February 3, 2026

Summary

The combination therapy of bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate (B/F/TAF) is a cornerstone in antiretroviral treatment (ART) for HIV-1. This segment is characterized by robust market growth driven by increasing HIV prevalence, favorable regulatory landscapes, and advancing patent protections. Investment considerations hinge on market demand, competitive positioning, regulatory status, patent life, and potential for development of next-generation therapies. This analysis provides a comprehensive overview of market dynamics, financial trajectories, investment risks, and growth prospects.

---

Market Overview

Global HIV Treatment Market Size

Metric	2022	Projected 2027	CAGR	Source
Market value	USD 30 billion	USD 46 billion	9.3%	[1]
HIV patients worldwide	38 million	41 million	2.4%	[2]

The global HIV treatment market, powered by antiretroviral therapies, is expected to maintain a CAGR of approximately 9.3% through 2027, fueled by expanding access in low-income regions and technological advancements.

Key Market Drivers

• Increasing HIV Incidence and Prevalence: Despite significant progress, an estimated 1.5 million new HIV infections occurred worldwide in 2021.[2]

• Path to UNAIDS 95-95-95 Targets: Emphasis on early diagnosis and sustained ART adherence increase demand for effective, tolerable, and simplified regimens.

• Advances in Drug Efficacy and Safety: New formulations like B/F/TAF offer improved safety profiles and convenience, boosting market uptake.

• Patent Protections & Regulatory Approvals: More than 60 countries have approved B/F/TAF, extending patent life until at least 2030.

---

Product Profile: Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate

Pharmacological Overview

Component	Mechanism	Advantages	Patent Status
Bictegravir (BIC)	HIV integrase strand transfer inhibitor (INSTI)	High barrier to resistance, once-daily dosing	Patented until 2030+[3]
Emtricitabine (FTC)	Nucleoside reverse transcriptase inhibitor	Well-established, safety profile	Generic status in multiple markets
Tenofovir Alafenamide (TAF)	Nucleotide reverse transcriptase inhibitor	Lower renal and bone toxicity relative to TDF	Patent until 2030+[4]

Advantages Over Competitors

• Simplified, one-tablet regimen
• Improved tolerability over TDF-based therapies
• Favorable pharmacokinetics enabling reduced dosages

Market Position

Initially launched by Gilead Sciences in 2019, the B/F/TAF regimen is marketed as Biktarvy, capturing a significant market share among single-tablet regimens (STRs). Its combined efficacy and safety profile have resulted in high physician prescribing rates.

---

Market Dynamics & Competitive Landscape

Major Competitors

Competitor	Composition	Market Share (%)	Key Differentiators	Regulatory Status	Estimated Patent Life
Biktarvy (Gilead)	BIC/FTC/TAF	45	High efficacy, safety, adherence	U.S.: till 2030+	2029-2034
Genvoya (Gilead)	TAF-based	15	Approved for specific populations	Patents till 2029	2029
Dolutegravir-based Regimens	DTG + NRTI	25	Increasing market share	Ongoing patent disputes	2024-2032

Market Entry and Growth Strategies

• Patent extensions via new formulations or combinations.
• Geographic expansion, especially in Asia and Africa.
• Pricing strategies to improve access.

Patent Expiry & Biosimilar/COPN Threats

• Key patents on Biktarvy expire 2030+ in major markets.
• The entry of biosimilars or generics post-expiry could dilute revenues.
• Patent litigations continue, impacting timing and market penetration.

---

Financial Trajectory & Investment Outlook

Revenue Projections

Year	Estimated Revenue (USD billion)	% of Total HIV Market	Key Assumptions	Sources
2022	4.5	15%	Continued market share, patent protection	[1], [3]
2023	4.9	16%	Slight market share increase	-
2024	5.2	17%	Stable market, patent litigation impact	-
2025	5.8	17%	Emerging markets expansion	-
2026	6.2	17%	Introduction of rival drugs	-

Cost & Profitability

• Estimated R&D investments: USD 1–2 billion over 5 years.
• Licensing & regulatory costs: 25–30% of revenues.
• Profit margins: 60–70% (expected to sustain amid patent protections).

Investment Horizon & Risk Factors

Risks	Impact	Mitigation
Patent expiry	Revenue decline	Patent extensions or pipeline diversification
Competitive drug entry	Market share erosion	Marketing & pricing strategies
Regulatory changes	Delays or restrictions	Proactive compliance & engagement
Pricing pressures	Profit margins	Tiered pricing, especially in emerging markets

---

Regulatory & Policy Environment

• US FDA approved Biktarvy in 2018.
• EMA approval obtained in 2019.
• WHO recommends integrase inhibitor-based regimens since 2019.
• Expansion driven by WHO prequalified status and national policies.

Patent & Data Exclusivity Policies

Region	Patent Protection Duration	Data Exclusivity Period	Notable Policies
US	20 years	5 years	Hatch-Waxman Act
EU	20 years	8+ years	Supplementary protection certificates (SPCs)
Emerging Markets	Varies	Varies	Often limited, high biosimilar potential

---

Comparison with Other Antiretroviral Drug Classes

Class	Examples	Advantages	Limitations
INSTIs	Bictegravir, Dolutegravir	High efficacy, tolerability	Resistance potential if nonadherent
NRTIs	FTC, TAF, TDF	Established, broad use	Toxicity issues with TDF
Protease Inhibitors	Darunavir	Potent activity	Side effect profile
Entry Inhibitors	Maraviroc	Specific targeting	Limited indications

---

Deep Market Penetration & Future Outlook

• Emerging Markets: Africa, Asia – strategies include tiered pricing, local manufacturing.
• Next-Generation Innovations: Long-acting injectable formulations, multipurpose therapies.
• Patent Challenges & Biosimilar Landscape: Key to long-term revenue stability.
• Pipeline Developments: Dual therapies, NS5A-like strategies, gene therapies.

---

FAQs

1. When does the patent protection for B/F/TAF expire?
Patent protection is expected to expire around 2030–2034 in major jurisdictions, allowing biosimilar entrants thereafter.

2. How does the revenue from B/F/TAF compare with other HIV treatments?
Biktarvy (marketed as B/F/TAF) holds approximately 45% of the STR market share, making it the leading single-tablet regimen.

3. What are the key risks to investment in this therapy?
Patent expiry, aggressive biosimilar competition, pricing pressures in emerging markets, and regulatory shifts.

4. What is the scope for geographic expansion?
Significant growth is expected in Africa, Asia-Pacific, and Latin America, driven by increasing healthcare access programs and partnerships.

5. How do regulatory changes impact the financial trajectory?
Favorable regulatory environments extend exclusivity; restrictive policies or patent disputes could delay or reduce revenues.

---

Key Takeaways

• The B/F/TAF combination remains a dominant, high-margin asset with solid growth prospects till its patent expiry, projected around 2030–2034.
• Market growth is driven by rising global HIV prevalence, adoption of simplified regimens, and regulatory acceptance.
• Competitive pressures from biosimilars and generics are imminent post-patent expiry, emphasizing the need for continuous pipeline innovation.
• Geographic expansion in emerging markets offers substantial, yet risky, growth opportunities.
• Strategic patent management, pipeline development, and market diversification are critical for sustained investment return.

---

References

[1] GlobalData. (2022). HIV Treatment Market Report.

[2] UNAIDS. (2022). Global HIV & AIDS Statistics.

[3] Gilead Sciences. (2022). Biktarvy Patent and Regulatory Status.

[4] U.S. Patent and Trademark Office. (2020). Patent expiration details for TAF compounds.

---

Note: This analysis is based on available public data up to Q1 2023, and investors should continuously monitor patent landscapes, regulatory updates, and clinical developments for comprehensive decision-making.